JOHN BELPERIO

Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease LOS ANGELES, CA NPI 1285659482

General Payments — all program years on this page

$258,327.31

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 263
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $18,089.24 across 11 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Boehringer Ingelheim Pharmaceuticals, Inc. $18,022.099
Zambon USA Ltd. $45.771
GlaxoSmithKline, LLC. $21.381

By program year

Program yearAmountRecords
2018 $60,341.9172
2019 $97,117.3094
2020 $25,249.2636
2021 $7,879.5714
2022 $29,464.7314
2023 $20,185.3022
2024 $18,089.2411

Records — PY2024 (11)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1116481073 GlaxoSmithKline, LLC. $21.38 05/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117948653 Boehringer Ingelheim Pharmaceuticals, Inc. $120.72 01/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 View at CMS
1117948655 Boehringer Ingelheim Pharmaceuticals, Inc. $140.00 01/31/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1117948657 Boehringer Ingelheim Pharmaceuticals, Inc. $556.10 05/19/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 View at CMS
1117948659 Boehringer Ingelheim Pharmaceuticals, Inc. $1,056.10 10/17/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 View at CMS
1117948661 Boehringer Ingelheim Pharmaceuticals, Inc. $1,968.75 01/31/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1117948663 Boehringer Ingelheim Pharmaceuticals, Inc. $14,040.00 01/31/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1117948665 Boehringer Ingelheim Pharmaceuticals, Inc. $26.80 06/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117948667 Boehringer Ingelheim Pharmaceuticals, Inc. $35.00 01/31/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117948669 Boehringer Ingelheim Pharmaceuticals, Inc. $78.62 05/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1147024867 Zambon USA Ltd. $45.77 05/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.